PRINCETON, N.J. -- Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted, for filing and review, the Biologics License Application (BLA) for ipilimumab for the treatment of adult patients with advanced melanoma who have been The comp

read more>>

KALAMAZOO, Mich. -- NephRx Corporation today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its lead product NX001 for the prevention of delayed graft function (DGF) in renal transplant recipientsNX001 is a kidney growth factor peptide that has de

read more>>

WALTHAM, Mass. -- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops antibody-based targeted anticancer products, today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation to its lorvotuzumab mertansine (formerly IMGN901) product candidate

read more>>

INDIANAPOLIS -- Eli Lilly and Company (NYSE: LLY) will halt development of semagacestat, a gamma secretase inhibitor being studied as a potential treatment for Alzheimer's disease, because preliminary results from two ongoing long-term Phase III studies showed it did not slow disease progression T

read more>>

ATLANTA, GA -- Spectrum, a health and science communications firm, announced the results of a global awareness campaign that "found" 24 percent more children identified with a rare, fatal, and rapid aging disease called ProgeriaThe findings are being shared at a Centers for Disease Control nationa

read more>>

Idebenone does not appear to improve neurologic function in pediatric patients with Friedreich's ataxia, according to the findings of a randomized phase 3 trialDavid R. Lynch, MD, PhD, with the University of Pennsylvania School of Medicine in Philadelphia, and colleagues report their findings in t

read more>>

AMSTERDAM, The Netherlands -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today announced that the Marketing Authorisation Application (MAA) for Glybera(R) remains on schedule following meetings with the European Medicine Agency (EMA) concerning T

read more>>

WESTON, MA, and PITTSBURGH, PA -- Biogen Idec (NASDAQ: BIIB) and Knopp Neurosciences today announced they have entered into an exclusive, worldwide license agreement under which Biogen Idec will develop and commercialize KNS-760704 (dexpramipexole) for the treatment of amyotrophic lateral sclerosis

read more>>

TUCSON, Ariz. -- The Muscular Dystrophy Association, which has invested almost $39 million in 2010 in worldwide research seeking treatments and cures for muscle diseases, today announced that it has awarded $14.1 million in new grants"Thanks to generous public support of MDA, we're able to keep fu

read more>>

NOVATO, Calif. -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that it has acquired ZyStor Therapeutics, Inc. (ZyStor), a privately-held biotechnology company developing enzyme replacement therapies (ERT) for the treatment of lysosomal storage disordersZyStor's lead product candidat

read more>>